The Biden administration on Friday released the next round of prescription drugs selected for Medicare price negotiations, including Ozempic — the blockbuster diabetes drug that’s also used for weight loss. The drug has faced public backlash over its high price, fueling demand for cheaper alternatives.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing the selection two weeks ahead of schedule. Administration officials did not share which drugs had been selected,

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.